All analyses in the extension were exploratory
Side effects are typically mild and may include temporary redness or soreness at the injection site, a brief "flushed" feeling, or short-lived lightheadedness
A warning about compounded semaglutide: the FDA does not approve compounded versions of GLP-1s, and the agency has issued specific warnings about safety risks in 2026
In research settings, it is studied for its apparent role in tissue repair, angiogenesis, nitric oxide system interactions, and musculoskeletal healing mechanisms in vitro and animal model studies
Genetic alteration, expression analysis, and in vitro evidence further support that reduced GLP-1 signaling is associated with worse survival across CRC and other cancers
By aligning visit structure with modern therapies, clinics can deliver better outcomes without longer appointments